Effect of 12-week intermittent calorie restriction compared to standard of care in patients with nonalcoholic fatty liver disease: a randomized controlled trial
DiscussionThis FLICR study may provide clinical evidence on ICR in the treatment of NAFLD in both obese and non-obese patients. The use of ICR in patients with NAFLD will improve the clinical outcomes of patients facing a shortage of effective medical therapy.Trial registrationThis trial was registered at the United States National Library of Medicine (NLM) at the National Institutes of Health. ClinicalTrials.gov NCT05309642. Registered on April 4, 2022. (Source: Trials)
Source: Trials - August 2, 2023 Category: Research Source Type: clinical trials
A Study to Test How Well Different Doses of BI 3006337 Are Tolerated by People With Overweight or Obesity and With Fatty Liver Disease
Conditions: Non-alcoholic Fatty Liver Disease; Obesity Interventions: Drug: BI 3006337; Drug: Placebo matching BI 3006337 Sponsor: Boehringer Ingelheim Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - August 1, 2023 Category: Research Source Type: clinical trials
Diet, Immunometabolism and Non-alcoholic Fatty Liver Disease
Conditions: Non-Alcoholic Fatty Liver Disease; Liver Fat; Obesity; Inflammation Interventions: Behavioral: Standard healthy eating advice; Behavioral: eTRE plus Mediterranean diet Sponsors: University College Dublin; St. James's Hospital, Ireland Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - August 1, 2023 Category: Research Source Type: clinical trials
A Study to Test How Well Different Doses of BI 3006337 Are Tolerated by People With Overweight or Obesity and With Fatty Liver Disease
Conditions: Non-alcoholic Fatty Liver Disease; Obesity Interventions: Drug: BI 3006337; Drug: Placebo matching BI 3006337 Sponsor: Boehringer Ingelheim Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - August 1, 2023 Category: Research Source Type: clinical trials
Diet, Immunometabolism and Non-alcoholic Fatty Liver Disease
Conditions: Non-Alcoholic Fatty Liver Disease; Liver Fat; Obesity; Inflammation Interventions: Behavioral: Standard healthy eating advice; Behavioral: eTRE plus Mediterranean diet Sponsors: University College Dublin; St. James's Hospital, Ireland Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - August 1, 2023 Category: Research Source Type: clinical trials
A Study to Test How Well Different Doses of BI 3006337 Are Tolerated by People With Overweight or Obesity and With Fatty Liver Disease
Conditions: Non-alcoholic Fatty Liver Disease; Obesity Interventions: Drug: BI 3006337; Drug: Placebo matching BI 3006337 Sponsor: Boehringer Ingelheim Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - August 1, 2023 Category: Research Source Type: clinical trials
